Jun 08, 2022

  • Corporate

Chugai Receives DX Grand Prix 2022 Awards in Digital Transformation Stocks (DX Stocks) 2022

  • The DX Stocks are jointly selected by METI and TSE to accelerate digital transformation of Japanese companies
  • Chugai receives DX Grand Prix 2022 Awards for the first time as a leading company in promoting digital transformation
  • Chugai is the only company in the pharmaceutical industry which has been listed among the DX Stocks for three consecutive years
DX Grand Prix 2022 logo

TOKYO, June 8, 2022 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it received DX Grand Prix 2022 Awards in “Digital Transformation Stocks (DX Stocks) 2022” selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE). From among TSE-listed companies, “DX Stocks” are designated to those companies, in each industrial category, that have established internal systems to promote digital transformation (DX) leading to increased corporate value, and have outstanding achievements in digital utilization. Chugai has been selected as a DX Stock for three consecutive years and received DX Grand Prix 2022 Awards as a leading company in DX implementation.

Thirty-three TSE-listed companies were selected in consideration of contribution to corporate value, and capability of DX realization. Chugai won the Grand Prix as a leading company in promoting DX as its growth strategy “TOP I 2030” is well linked with “CHUGAI DIGITAL VISION 2030,” the company’s vision for promoting DX, and its achievements in a series of initiatives for drug discovery and manufacturing processes, as well as those for healthcare professionals and patients. These comprehensive efforts were highly evaluated.

“We are very pleased to win the Grand Prix this year. 2021 was the final year of the Phase 1 (Change our people & culture) of CHUGAI DIGITAL VISION 2030, which is our roadmap for 2030. We successfully achieved many outcomes in strengthening our foundation, including reforming our corporate culture and enhancing digital talent,” said Chugai’s Executive Vice President and Head of Digital Transformation Unit, Satoko Shisai. “We’ve shifted to the Phase 2 (Change our business) from this year. Aiming at innovative novel drug discovery (DxD3*) with digital technologies, which is central of our vision, we will further gear up for accelerating utilization of data, advancing platform for enhancing digital talent, promoting open innovation in digital technology, and others.”

*DX for Drug Discovery and Development

In order to realize its goal of becoming a top innovator in the healthcare industry, Chugai formulated a growth strategy “TOP I 2030,” which is consisted of two pillars of “global first-class drug discovery” and a “futuristic business model.” DX is positioned as one of the key drivers to achieve the target. In accelerating DX, Chugai is committed to transforming its business and providing healthcare solutions that will change society through three basic strategies of CHUGAI DIGITAL VISION 2030: 1) Strengthen the digital platform, 2) Optimize all value chains, and 3) Digital transformation for drug discovery and development.


CHUGAI DIGITAL official note (in Japanese only)

DX Stocks 2022 logo


  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top